Talimogene Laherparepvec
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Talimogene Laherparepvec
- Talimogene Laherparepvec: From Melanoma (Skin/Lymph Node Metastasis) to CMM7
Using no specific skill (this is a direct content-generation task per the explicit report template already provided in the prompt).
Talimogene Laherparepvec: From Melanoma (Skin/Lymph Node Metastasis) to CMM7
One-Sentence Summary
Talimogene laherparepvec (T-VEC) is an oncolytic HSV-1-based immunotherapy approved for intratumoral injection in unresectable melanoma with skin/lymph node metastases. The TxGNN model predicts it may be effective for CMM7 (a cutaneous malignant melanoma susceptibility subtype), but no clinical trials and no literature currently support this specific prediction — it is based solely on knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Melanoma with skin/lymph node metastases (unresectable) |
| Predicted New Indication | CMM7 |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (HSV-1)-based immunotherapy engineered to express GM-CSF, already approved for local intratumoral injection in unresectable melanoma with skin and lymph node metastases; mechanistically it may be applicable to CMM7.
CMM7 (cutaneous malignant melanoma susceptibility locus 7) represents a genetic subtype within the same melanoma disease spectrum as the drug’s approved indication, giving the prediction reasonable biological plausibility as a within-lineage extension rather than a cross-tumor-type leap. However, this mechanistic link has not been validated by any subtype-specific clinical trial or publication, and CMM7 as a genetically defined susceptibility classification (rather than a distinct clinical entity) raises questions about how this indication would translate into an actual treatable population.
Other TxGNN-predicted candidates for this drug (pediatric leptomeningeal melanoma, uveal melanoma, and several non-melanoma carcinomas — glottis SCC, occult lung SCC, rectal cloacogenic carcinoma, gallbladder adenosquamous carcinoma) show progressively weaker mechanistic rationale, particularly for non-melanoma histologies where intratumoral injectability and antigenic relevance to T-VEC’s mechanism are questionable. All seven predictions share the same evidentiary limitation: model score only, no supporting trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The drug is currently not marketed in this jurisdiction (0 licenses on file), so no authorization records are available for tabulation.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (oncolytic viral therapy, HSV-1-based, GM-CSF-expressing) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | As a live attenuated oncolytic virus, administration requires institutional biosafety/infection-control precautions (e.g., avoiding contact with immunocompromised individuals, herpes-naive close contacts, and pregnant individuals); specifics not confirmed in current evidence pack |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All seven TxGNN-predicted indications are rated L5 (model prediction only) with zero supporting clinical trials or literature. Additionally, a blocking data gap exists for TFDA/FDA label warnings and contraindications (DG001), which prevents any S1 safety pre-assessment.
To proceed, the following is needed:
- Resolve DG001 (blocking): obtain and parse the official package insert for warnings/contraindications from the relevant regulatory agency
- Resolve DG002: obtain detailed mechanism of action data via DrugBank API to strengthen mechanistic-link analysis
- Generate or identify subtype-specific clinical/literature evidence for CMM7 before advancing beyond S0
- Assess route compatibility (intratumoral injection feasibility) for each candidate indication, particularly deep-visceral or CNS-involving sites (leptomeningeal, gallbladder, lung occult SCC)
- Given the weak mechanistic basis for non-melanoma candidates (ranks 4–7), consider deprioritizing these in favor of melanoma-lineage subtypes (ranks 1–3)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.